Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts

Iv Kraja, Renjie Bing, Nao Hiwatashi, Bernard Rousseau, Danielle Nalband, Kent Kirshenbaum, Ryan C. Branski

Research output: Contribution to journalArticle

Abstract

Objective: An obstacle to clinical use of RNA-based gene suppression is instability and inefficiency of current delivery modalities. Nanoparticle delivery likely holds great promise, but the kinetics and transfection conditions must be optimized prior to in vivo utility. We investigated a RNA nanoparticle complex incorporating a lipitoid transfection reagent in comparison to a commercially available reagent. Study Design: In vitro. Methods: We investigated which variables influence transfection efficiency of lipitoid oligomers and a commercially available reagent across species, in vitro. These variables included duration, dose, and number of administrations, as well as serum and media conditions. The target gene was Smad3, a signaling protein in the transforming growth factor-β cascade implicated in fibroplasia in the vocal folds and other tissues. Results: The two reagents suppressed Smad3 mRNA for up to 96 hours; lipitoid performed favorably and comparably. Both compounds yielded 60% to 80% mRNA knockdown in rat, rabbit, and human vocal fold fibroblasts (P < 0.05 relative to control). Dose and number of administrations played a significant role in gene suppression (P < 0.05). Suppression was more dose-sensitive with lipitoid. At a constant siRNA concentration, a 50% decrease in gene expression was observed in response to a five-fold increase in lipitoid concentration. Increased number of administrations enhanced gene suppression, ∼45% decrease between one and four administrations. Neither serum nor media type altered efficiency. Conclusion: Lipitoid effectively knocked down Smad3 expression across multiple transfection conditions. These preliminary data are encouraging, and lipitoid warrants further investigation with the goal of clinical utility. Level of Evidence: NA. Laryngoscope, 127:E231–E237, 2017.

Original languageEnglish (US)
Pages (from-to)E231-E237
JournalLaryngoscope
Volume127
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Vocal Cords
Small Interfering RNA
Transfection
Fibroblasts
Nanoparticles
Genes
RNA
Laryngoscopes
Messenger RNA
Transforming Growth Factors
Serum
Rabbits
Gene Expression
Proteins
In Vitro Techniques

Keywords

  • fibroblast
  • lipitoid
  • Lipofectamine
  • siRNA
  • Smad3
  • transfection
  • vocal fold
  • voice

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Kraja, I., Bing, R., Hiwatashi, N., Rousseau, B., Nalband, D., Kirshenbaum, K., & Branski, R. C. (2017). Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts. Laryngoscope, 127(7), E231-E237. https://doi.org/10.1002/lary.26432

Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts. / Kraja, Iv; Bing, Renjie; Hiwatashi, Nao; Rousseau, Bernard; Nalband, Danielle; Kirshenbaum, Kent; Branski, Ryan C.

In: Laryngoscope, Vol. 127, No. 7, 01.07.2017, p. E231-E237.

Research output: Contribution to journalArticle

Kraja, I, Bing, R, Hiwatashi, N, Rousseau, B, Nalband, D, Kirshenbaum, K & Branski, RC 2017, 'Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts', Laryngoscope, vol. 127, no. 7, pp. E231-E237. https://doi.org/10.1002/lary.26432
Kraja, Iv ; Bing, Renjie ; Hiwatashi, Nao ; Rousseau, Bernard ; Nalband, Danielle ; Kirshenbaum, Kent ; Branski, Ryan C. / Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts. In: Laryngoscope. 2017 ; Vol. 127, No. 7. pp. E231-E237.
@article{cbf0dad9e52548b583a132f4a7cc7642,
title = "Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts",
abstract = "Objective: An obstacle to clinical use of RNA-based gene suppression is instability and inefficiency of current delivery modalities. Nanoparticle delivery likely holds great promise, but the kinetics and transfection conditions must be optimized prior to in vivo utility. We investigated a RNA nanoparticle complex incorporating a lipitoid transfection reagent in comparison to a commercially available reagent. Study Design: In vitro. Methods: We investigated which variables influence transfection efficiency of lipitoid oligomers and a commercially available reagent across species, in vitro. These variables included duration, dose, and number of administrations, as well as serum and media conditions. The target gene was Smad3, a signaling protein in the transforming growth factor-β cascade implicated in fibroplasia in the vocal folds and other tissues. Results: The two reagents suppressed Smad3 mRNA for up to 96 hours; lipitoid performed favorably and comparably. Both compounds yielded 60{\%} to 80{\%} mRNA knockdown in rat, rabbit, and human vocal fold fibroblasts (P < 0.05 relative to control). Dose and number of administrations played a significant role in gene suppression (P < 0.05). Suppression was more dose-sensitive with lipitoid. At a constant siRNA concentration, a 50{\%} decrease in gene expression was observed in response to a five-fold increase in lipitoid concentration. Increased number of administrations enhanced gene suppression, ∼45{\%} decrease between one and four administrations. Neither serum nor media type altered efficiency. Conclusion: Lipitoid effectively knocked down Smad3 expression across multiple transfection conditions. These preliminary data are encouraging, and lipitoid warrants further investigation with the goal of clinical utility. Level of Evidence: NA. Laryngoscope, 127:E231–E237, 2017.",
keywords = "fibroblast, lipitoid, Lipofectamine, siRNA, Smad3, transfection, vocal fold, voice",
author = "Iv Kraja and Renjie Bing and Nao Hiwatashi and Bernard Rousseau and Danielle Nalband and Kent Kirshenbaum and Branski, {Ryan C.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1002/lary.26432",
language = "English (US)",
volume = "127",
pages = "E231--E237",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts

AU - Kraja, Iv

AU - Bing, Renjie

AU - Hiwatashi, Nao

AU - Rousseau, Bernard

AU - Nalband, Danielle

AU - Kirshenbaum, Kent

AU - Branski, Ryan C.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Objective: An obstacle to clinical use of RNA-based gene suppression is instability and inefficiency of current delivery modalities. Nanoparticle delivery likely holds great promise, but the kinetics and transfection conditions must be optimized prior to in vivo utility. We investigated a RNA nanoparticle complex incorporating a lipitoid transfection reagent in comparison to a commercially available reagent. Study Design: In vitro. Methods: We investigated which variables influence transfection efficiency of lipitoid oligomers and a commercially available reagent across species, in vitro. These variables included duration, dose, and number of administrations, as well as serum and media conditions. The target gene was Smad3, a signaling protein in the transforming growth factor-β cascade implicated in fibroplasia in the vocal folds and other tissues. Results: The two reagents suppressed Smad3 mRNA for up to 96 hours; lipitoid performed favorably and comparably. Both compounds yielded 60% to 80% mRNA knockdown in rat, rabbit, and human vocal fold fibroblasts (P < 0.05 relative to control). Dose and number of administrations played a significant role in gene suppression (P < 0.05). Suppression was more dose-sensitive with lipitoid. At a constant siRNA concentration, a 50% decrease in gene expression was observed in response to a five-fold increase in lipitoid concentration. Increased number of administrations enhanced gene suppression, ∼45% decrease between one and four administrations. Neither serum nor media type altered efficiency. Conclusion: Lipitoid effectively knocked down Smad3 expression across multiple transfection conditions. These preliminary data are encouraging, and lipitoid warrants further investigation with the goal of clinical utility. Level of Evidence: NA. Laryngoscope, 127:E231–E237, 2017.

AB - Objective: An obstacle to clinical use of RNA-based gene suppression is instability and inefficiency of current delivery modalities. Nanoparticle delivery likely holds great promise, but the kinetics and transfection conditions must be optimized prior to in vivo utility. We investigated a RNA nanoparticle complex incorporating a lipitoid transfection reagent in comparison to a commercially available reagent. Study Design: In vitro. Methods: We investigated which variables influence transfection efficiency of lipitoid oligomers and a commercially available reagent across species, in vitro. These variables included duration, dose, and number of administrations, as well as serum and media conditions. The target gene was Smad3, a signaling protein in the transforming growth factor-β cascade implicated in fibroplasia in the vocal folds and other tissues. Results: The two reagents suppressed Smad3 mRNA for up to 96 hours; lipitoid performed favorably and comparably. Both compounds yielded 60% to 80% mRNA knockdown in rat, rabbit, and human vocal fold fibroblasts (P < 0.05 relative to control). Dose and number of administrations played a significant role in gene suppression (P < 0.05). Suppression was more dose-sensitive with lipitoid. At a constant siRNA concentration, a 50% decrease in gene expression was observed in response to a five-fold increase in lipitoid concentration. Increased number of administrations enhanced gene suppression, ∼45% decrease between one and four administrations. Neither serum nor media type altered efficiency. Conclusion: Lipitoid effectively knocked down Smad3 expression across multiple transfection conditions. These preliminary data are encouraging, and lipitoid warrants further investigation with the goal of clinical utility. Level of Evidence: NA. Laryngoscope, 127:E231–E237, 2017.

KW - fibroblast

KW - lipitoid

KW - Lipofectamine

KW - siRNA

KW - Smad3

KW - transfection

KW - vocal fold

KW - voice

UR - http://www.scopus.com/inward/record.url?scp=85020923626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020923626&partnerID=8YFLogxK

U2 - 10.1002/lary.26432

DO - 10.1002/lary.26432

M3 - Article

C2 - 27996099

AN - SCOPUS:85020923626

VL - 127

SP - E231-E237

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 7

ER -